Pyrazole, isoxazole and imidazole derivatives for treating diseases linked to protein aggregation and neurodegenerative diseases

摘要

The disclosure relates to a compound represented by formula (E), wherein the variables are as defined in the specification. These compound represented by the formula (E) are suitable for the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases, wherein the disease is selected from the group consisting of Parkinson's disease, prion disease, Alzheimer's disease, multiple system atrophy, Diffuse Lewy body disease, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxias and other Poly-Q diseases, hereditary cerebral amyloid angiopathy, familial amyloid polyneuropathy, primary systemic amyloidosis (AL amyloidosis), reactive systemic amyloidosis (AA amyloidosis), type II diabetes, injection-localized amyloidosis, beta-2 microglobulin amyloidosis, hereditary non-neuropathic amyloidosis, and Finnish hereditary systemic amyloidosis. The disclosure also relates to pharmaceutical and diagnostic compositions comprising the compound of formula (E) as well as to a kit for preparing a detectably labelled compound of formula (E).